Xenon Pharmaceuticals (XENE) Long-Term Deferred Tax (2018 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Long-Term Deferred Tax of $12.4 million for Q1 2026, up 14.14% year-over-year from $10.9 million in Q1 2025, and down 3.47% quarter-over-quarter from $12.9 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Long-Term Deferred Tax (2018 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Long-Term Deferred Tax for 9 consecutive years, with $12.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 14.14% year-over-year to $12.4 million; the TTM figure through Mar 2026 stood at $12.4 million (up 14.14% YoY), while the FY2025 annual figure was $12.9 million, up 33.09% from the prior year.
- Long-Term Deferred Tax retreated to $12.4 million in Q1 2026 per XENE's latest filing, from $12.9 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $12.9 million in Q4 2025 and bottomed at $207000.0 in Q1 2022.
- Historically, Long-Term Deferred Tax has averaged $4.4 million across 5 years, with a median of $733000.0 in 2024.
- Annual changes were most pronounced in 2022 — Long-Term Deferred Tax slumped 99.05% — and 2025, when it surged 2619.75%.
- Xenon Pharmaceuticals' Long-Term Deferred Tax stood at $509000.0 in 2022, then jumped by 57.56% to $802000.0 in 2023, then soared by 1105.24% to $9.7 million in 2024, then jumped by 33.09% to $12.9 million in 2025, then retreated by 3.47% to $12.4 million in 2026.
- Business Quant data shows XENE's Long-Term Deferred Tax at $12.4 million in Q1 2026, $12.9 million in Q4 2025, and $11.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.36 Mn |
| Mar 31, 2026 | 12.42 Mn |
| Dec 31, 2025 | 12.86 Mn |
| Sep 30, 2025 | 11.75 Mn |
| Jun 30, 2025 | 11.05 Mn |
| Mar 31, 2025 | 10.88 Mn |
| Dec 31, 2024 | 9.67 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 733,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 802,000.00 |
| Sep 30, 2023 | 601,000.00 |
| Jun 30, 2023 | 445,000.00 |
| Mar 31, 2023 | 221,000.00 |
| Dec 31, 2022 | 509,000.00 |
| Sep 30, 2022 | 514,000.00 |
| Jun 30, 2022 | 311,000.00 |
| Mar 31, 2022 | 207,000.00 |
| Dec 31, 2021 | 53.45 Mn |
| Sep 30, 2021 | 811,000.00 |